Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chelsea Katz

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Gynecologic Oncology Reports|July 31, 2025
Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experienceHelen Toma, Rebeca Kelly, Chelsea Katz, et al.
JAMA Network Open|January 23, 2026
Opioid Treatment Programs' Medicaid Patient Retention RatesDylan E DeLisle, Tami L Mark, Chelsea Katz, et al.
Biomolecules|November 27, 2021
Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of TimeMichelle Bilbao, Chelsea Katz, Stephanie L Kass, et al.
JMIR Cardio|November 24, 2019
Provider- and Patient-Related Barriers to and Facilitators of Digital Health Technology Adoption for Hypertension Management: Scoping ReviewRamya Sita Palacholla, Nils Fischer, Amanda Coleman, et al.
Drug and Alcohol Dependence Reports|October 2, 2025
Identifying Opioid Treatment Programs in Medicaid claims data to support quality improvementBarrett Wallace Montgomery, Tami L Mark, William Dowd, et al.
Journal of Substance Use and Addiction Treatment|November 23, 2025
Retention among Medicaid beneficiaries in opioid treatment programs in CaliforniaWilliam N Dowd, Daniel H Barch, Tami L Mark, et al.
JAMA Network Open|April 22, 2026
Cascade of Care for Opioid Use Disorder Among Medicaid BeneficiariesThanh T Lu, William N Dowd, Tami L Mark, et al.
Genes and Immunity|April 28, 2026
Immunological and prognostic impact of NRF2 in high grade serous ovarian cancerSamera H Hamad, Chelsea Katz, Helen Toma, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Gynecologic Oncology Reports|July 31, 2025
Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experienceHelen Toma, Rebeca Kelly, Chelsea Katz, et al.
JAMA Network Open|January 23, 2026
Opioid Treatment Programs' Medicaid Patient Retention RatesDylan E DeLisle, Tami L Mark, Chelsea Katz, et al.
Biomolecules|November 27, 2021
Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of TimeMichelle Bilbao, Chelsea Katz, Stephanie L Kass, et al.
JMIR Cardio|November 24, 2019
Provider- and Patient-Related Barriers to and Facilitators of Digital Health Technology Adoption for Hypertension Management: Scoping ReviewRamya Sita Palacholla, Nils Fischer, Amanda Coleman, et al.
Drug and Alcohol Dependence Reports|October 2, 2025
Identifying Opioid Treatment Programs in Medicaid claims data to support quality improvementBarrett Wallace Montgomery, Tami L Mark, William Dowd, et al.
Journal of Substance Use and Addiction Treatment|November 23, 2025
Retention among Medicaid beneficiaries in opioid treatment programs in CaliforniaWilliam N Dowd, Daniel H Barch, Tami L Mark, et al.
JAMA Network Open|April 22, 2026
Cascade of Care for Opioid Use Disorder Among Medicaid BeneficiariesThanh T Lu, William N Dowd, Tami L Mark, et al.
Genes and Immunity|April 28, 2026
Immunological and prognostic impact of NRF2 in high grade serous ovarian cancerSamera H Hamad, Chelsea Katz, Helen Toma, et al.
Pageof 1